Niki BioSolutions (NIKI) vs Passage Bio (PASG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Passage Bio (PASG) has outperformed Niki BioSolutions (NIKI) over the past year, losing 54.3% versus a loss of 82.1%. Over five years, PASG leads with a -98.1% price change compared with -98.3% for NIKI. Niki BioSolutions is the larger company by market cap ($13.1 million vs $12.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NIKI | PASG |
|---|---|---|
| Share price | $4.19 | $3.83 |
| Market cap | $13.07M | $12.32M |
| 1-day change | -3.00% | +2.68% |
| YTD return | -59.25% | -67.97% |
| 1-year return | -82.07% | -54.35% |
| 5-year return | -98.33% | -98.06% |
| EPS (TTM) | $-2.90 | $-11.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $24.00 | $20.00 |
| 52-week low | $4.10 | $3.29 |
| Distance from 52-week high | -82.54% | -80.85% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +304.70% |
| Average volume | 157.52K | 26.11K |
| Shares outstanding | 2.94M | 3.22M |
| Employees | 1 | 24 |
| Sector | Industrials | Health Care |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PASG has outperformed NIKI by 27.7 percentage points over the past year.
- The two companies sit in different sectors: Niki BioSolutions in Industrials and Passage Bio in Health Care.
About Niki BioSolutions
NIKI stock →Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa.
Industrials · Industrial Machinery/Components · 1 employees
About Passage Bio
PASG stock →Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 24 employees
NIKI vs PASG FAQ
Which is bigger, Niki BioSolutions or Passage Bio?
Niki BioSolutions (NIKI) is larger, with a market capitalization of $13.07M compared with $12.32M for Passage Bio (PASG).
Which stock has performed better over the past year, NIKI or PASG?
PASG returned -54.35% over the past 12 months, compared with -82.07% for NIKI (price return, excluding dividends). Past performance does not predict future results.
Are Niki BioSolutions and Passage Bio in the same industry?
No. Niki BioSolutions is in the Industrials sector, while Passage Bio is in Health Care.